Clinical evaluation of AA-673 tablets in patients with refrectory perannial nasal allergy

The therapeutic effects and safety of AA-673 tablets were studied in 54 patients with perennial nasal allergy refractory to other oral antiallergic agents.The patients were prescribed a 50 mg tablet of AA-673 three times daily for 4 weeks.Evaluation of the final global improvement revealed “moderate improvement or better” in 23% of the patients, and “slight improvement or better” in 65%.In comparison between groups of the pretreated agents, the evaluation suggested difference between each groups.Side effects were observed in 4 patients (7.4%), but they were mild and transient.AA-673 tablets were considered to be useful for patients with perennial nasal allergy refractory to other oral antiallergic agents.